Fred Poordad

1.3k citations

45 papers · 586 indexed · h-index 14

Hepatology top 2%
- Hepatitis C virus research 25
- Liver Disease and Transplantation 4
Epidemiology top 10%
- Liver Disease Diagnosis and Treatment 12
- Hepatitis B Virus Studies 11
Infectious Diseases
- HIV/AIDS drug development and treatment 11
Rheumatology
- Systemic Lupus Erythematosus Research 7
Cell Biology
Genetics
- Chronic Lymphocytic Leukemia Research 9
Immunology
- Immunodeficiency and Autoimmune Disorders 3

Co-authors: Mina O. Rakoski Eric Lawitz Thao Tran Paul Martin Patrick Marcellin Marı́a Buti Ewa Janczewska Sivi Ouwerkerk‐Mahadevan
Cited by: Hepatology Epidemiology Infectious Diseases
Journals: SHILAP Revista de lepidopterología (1 paper)Gastroenterology (17 papers)Hepatology (3 papers)
Partner nations: United States Germany Spain

In The Last Decade

Fred Poordad

44 papers receiving 567 citations

Peers

Countries citing papers authored by Fred Poordad

Since Specialization

Citations

This map shows the geographic impact of Fred Poordad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Poordad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Poordad more than expected).

Fields of papers citing papers by Fred Poordad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Poordad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Poordad. The network helps show where Fred Poordad may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Fred Poordad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fred Poordad Line = papers co-authored together Fred Poordad links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	S4297 A Rare Sporo-Tricks Post Liver Transplant The American Journal of Gastroenterology ·Keerthi Thallapureddy,Courtney Thomas,Eugenia Tsai,Lisa D. Pedicone,Jan Petrášek,Fabian Rodas,Carmen Landaverde,Eric Lawitz,Fred Poordad,Andrés Gómez-Aldana	2024	1
2	BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial Hepatology ·Eric Lawitz,Diane E. Shevell,Giridhar Tirucherai,Shuyan Du,Warner Chen,Uma Kavita,Angie Coste,Fred Poordad,M.A. Karsdal,Mette Juul Nielsen,Zachary Goodman,Edgar D. Charles	2021	71
3	Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection Journal of Viral Hepatitis ·Eric Lawitz,Fred Poordad,Leah J. Anderson,Michelle Vesay,Michelle M. Kelly,Hong Liu,Wei Gao,Doreen Fernsler,Ernest Asante‐Appiah,Michael Robertson,George J. Hanna,Eliav Barr,Joan R. Butterton,Kris V. Kowdley,Tarek Hassanein,Amandeep Sahota,Stuart C. Gordon,Wendy W. Yeh	2019	5
4	752 High SVR Rates With the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection Gastroenterology ·Fred Poordad,Franco Felizarta,Stanley Wang,Armen Asatryan,Tarek Hassanein,Humberto Aguilar,Jacob Lalezari,J. Scott Overcash,Teresa I. Ng,Sandra Lovell,Chih‐Wei Lin,Jens Kort,Federico Mensa	2016	2
5	High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study Journal of Hepatology ·Fred Poordad,Stuart C. Gordon,Armen Asatryan,Franco Felizarta,Robert Reindollar,Charles Landis,Michael Fried,David Bernstein,Teresa I. Ng,C.-W. Lin,R. Liu,Jens Kort,Federico Mensa	2016	16
6	Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection Journal of Hepatology ·Graham R. Foster,Edward Gane,Armen Asatryan,S. Pol,Fred Poordad,John M. Vierling,Jens Kort,Ching‐Chih Lin,Sandra Lovell,Teresa I. Ng,Federico Mensa	2016	2
7	Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis C Antiviral Therapy ·Jacob Lalezari,Terry Box,William O’Riordan,Purvi Mehra,Tuan Nguyen,Fred Poordad,Edwin DeJesus,Paul Y. Kwo,Eliot Godofsky,Shannon Lawrence,Gloria Dubuc-Patrick,Jie Chen,Joseph McCarville,Keith Pietropaolo,Xiao-Jian Zhou,J. Sullivan-Bolyai,Douglas L. Mayers	2013	9
8	Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin Hepatology ·Ira M. Jacobson,Patrick Marcellin,Stefan Zeuzem,Mark Sulkowski,Rafael Esteban,Fred Poordad,Savino Bruno,Margaret Burroughs,Lisa D. Pedicone,Navdeep Boparai,Weiping Deng,Mark J. DiNubile,Keith Gottesdiener,Clifford A. Brass,Janice K. Albrecht,Jean-Pierre Bronowicki	2012	47
9	594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies Gastroenterology ·Mark Sulkowski,Stuart K. Roberts,Nezam H. Afdhal,Pietro Andreoné,M. Diago,Stanislas Pol,Fred Poordad,Stefan Zeuzem,Leif Bengtsson,Don Luo,James Witek,Nathalie Adda	2012	3
10	645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT Journal of Hepatology ·A. Sanyal,K. Mullen,N M Bass,T. Frederick,Fred Poordad,Ji Eun Hee,Kunal Merchant,Enoch Bortey,William P. Forbes	2012	6
11	Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient HPB ·Nicholas N. Nissen,Vijay G. Menon,Catherine Bresee,Tram T. Tran,Alagappan Annamalai,Fred Poordad,Jeffrey H. Fair,Andrew S. Klein,Brendan Boland,Steven D. Colquhoun	2011	19
12	Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia Journal of Medical Economics ·Fred Poordad,Dickens Theodore,Jane Sullivan,Kelly M. Grotzinger	2011	18
13	1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS Journal of Hepatology ·E. Läwitz,I. Gaultier,Fred Poordad,DE Cohen,Rajeev Menon,Lois Larsen,Thomas Podsadecki,Barry Bernstein	2011	6
14	Four-Week Therapy With Peginterferon Alfa-2B/Ribavirin Effectively Predicts Sustained Virologic Response in Treatment-NaïVE and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Gastroenterology ·John M. Vierling,Eric Lawitz,Fred Poordad,Mark Sulkowski,Marc Bourlière,Marı́a Buti,Curtis Cooper,Joseph Galati,Janice K. Albrecht,Navdeep Boparai,Clifford A. Brass,Margaret Burroughs,Vilma Sniukiene,Savino Bruno	2011	1
15	195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY Journal of Hepatology ·A. K. Sanyal,N M Bass,Fred Poordad,Mahboobeh Sheikh,K Mullen,Samuel H. Sigal,T. Frederick,Richard W. Brown,Binus Bhandari,Shahriar Sedghi,Kunal Merchant,S. Huang,Audrey L. Shaw,Enoch Bortey,William P. Forbes	2010	7
16	Big Changes Are Coming in Hepatitis C Current Gastroenterology Reports ·Fred Poordad	2010	15
17	Screening for hepatitis B in chemotherapy patients: survey of current oncology practices Alimentary Pharmacology & Therapeutics ·Thao Tran,Mina O. Rakoski,Paul Martin,Fred Poordad	2009	48
18	Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin Fred Poordad,Norbert Bräu,Eric Lawitz,Mitchell L. Shiffman,John G. McHutchison,Andrew J. Muir,Greg Galler,Jonathan McCone,Lisa M. Nyberg,William M. Lee,Reem Ghalib,Eugene R. Schiff,Joseph Galati,Bruce R. Bacon,Steven K. Herrine,Alexandra L. Gibas,John W. King,Clifford A. Brass,Janice K. Albrecht,Mark Sulkowski	2008	1
19	ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAı‥VE HBEAG PATIENTS (ETV 022/901) Ting‐Tsung Chang,You‐Chen Chao,Sabahattin Kaymakoğlu,Hugo Cheinquer,Mário Guimarães Pessôa,Robert G. Gish,Fred Poordad,Joanna Yang,H. Brett‐Smith,R. Hindes	2006	19
20	Emerging Role of Transplantation for Primary Liver Cancers The Cancer Journal ·Nicholas N. Nissen,Emanuel Cavazzoni,Tram T. Tran,Fred Poordad	2004	9

About Fred Poordad

Fred Poordad is a scholar working on Hepatology, Genetics and Infectious Diseases, having authored 45 papers that have together received 586 indexed citations. Recurring topics across this work include Hepatitis C virus research (25 papers), Liver Disease Diagnosis and Treatment (12 papers), Hepatitis B Virus Studies (11 papers), HIV/AIDS drug development and treatment (11 papers), Chronic Lymphocytic Leukemia Research (9 papers), Systemic Lupus Erythematosus Research (7 papers), Liver Disease and Transplantation (4 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). The work is most often cited by research in Hepatology (487 citations), Epidemiology (469 citations) and Infectious Diseases (100 citations). Fred Poordad has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Mina O. Rakoski, Eric Lawitz, Thao Tran, Paul Martin, Patrick Marcellin, Marı́a Buti, Ewa Janczewska, Sivi Ouwerkerk‐Mahadevan, Oliver Lenz and Mark Sulkowski. Their work appears in journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact